

Xatmep[™] (methotrexate) – New drug approval

- On April 26, 2017, <u>Silvergate Pharmaceuticals announced</u> the FDA approval of <u>Xatmep</u> (<u>methotrexate</u>) oral solution for the following:
 - Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multiphase, combination chemotherapy maintenance regimen.
 - Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
- Methotrexate is also available as <u>tablets</u> and various <u>injection</u> formulations. Refer to individual drug labels for specific indication information.
- The safety and effectiveness of Xatmep in pediatric patients with ALL were established as part of a
 multi-phase, combination chemotherapy maintenance regimen, and for the management of pediatric
 patients with active pJIA. The clinical trials in patients with pJIA were performed using other
 formulations of methotrexate.
- Xatmep carries a boxed warning for severe toxic reactions, including embryo-fetal toxicity.
- Xatmep is contraindicated in pregnancy in patients with non-malignant diseases and in patients with severe hypersensitivity to methotrexate.
- Warnings and precautions of Xatmep include bone marrow suppression, serious infections, renal
 toxicity and increased toxicity with renal impairment, gastrointestinal toxicity, hepatic toxicity,
 pulmonary toxicity, hypersensitivity and dermatologic reactions, secondary malignancies, ineffective
 immunization and risks associated with live vaccines, effects on reproduction, increased toxicity due
 to third-space accumulation, soft tissue and bone toxicity with radiation therapy, laboratory tests, and
 risk of improper dosing.
- The most common adverse reactions with methotrexate use are ulcerative stomatitis, leukopenia, nausea, abdominal distress, and elevated liver function tests. Other frequently reported adverse reactions are malaise, fatigue, chills and fever, dizziness, and decreased resistance to infection.
- The recommended dosing regimen of Xatmep for the treatment of ALL in multi-agent combination therapy maintenance regimens is 20 mg/m² administered orally once weekly.
- The recommended dosing regimen of Xatmep for the treatment of pJIA is 10 mg/m² administered orally once weekly.
- Silvergate Pharmaceuticals' launch plans for Xatmep are pending. Xatmep will be available as a 2.5 mg/mL oral solution. Xatmep will be available through an extensive network of pharmacies and a qualified mail-order service.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.